🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Aarey Drugs & Pharmaceuticals Limited AAREYDRUGS NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.aareydrugs.com
Company Profile ↓
₹95.79
+45.60% 1Y
Mkt Cap₹319.50 Cr
P/E75.43
P/B1.89
52W High₹99.25
52W Low₹50.75
Book Value₹52.87
EPS (TTM)₹1.27

Company Overview

Aarey Drugs & Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients, intermediates, and specialty chemicals for various industrial applications in India. The company offers intermediates, including mono methyl urea, di methyl urea, ortho para nitro anisole, 2-bromomethyl-1,3-dioxolane, and uracil. It also provides active pharmaceutical ingredients, such as metformin HCl, mefenamic acid, and doxofylline. In addition, the company trades chemicals and solvents, including aromatic chemicals, chemical acids, chlor-alkali, glycols and glycol ethers, fiber intermediates, and acetates and esters, as well as industrial alcohols, ketones, amines, oleochemicals, intermediates, olefins, phosphates, fertilizers, monomers, and chemicals. It serves pharmaceutical formulation manufacturers and pharmaceutical merchant exporters. Aarey Drugs & Pharmaceuticals Limited was incorporated in 1990 and is headquartered in Mumbai, India.

Recent Developments

  • Mar 2026 Revenue of ₹472.27 Cr (-0.4% YoY); net profit ₹3.97 Cr.
  • Trailing 12 Months Year-on-year growth — revenue -56.3%, earnings -25.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR 4.6%, profit CAGR 1.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:4.58%
1 Year:-56.30%

Compounded Profit Growth

5 Years:1.71%
1 Year:-25.00%

Stock Price Performance

1 Year:+45.60%
6 Months:+31.69%
3 Months:+19.38%
1 Month:+17.10%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 93% of range
₹50.75 ₹99.25
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)69.38 · Neutral
Price Performance
1M+17.10%
3M+19.38%
6M+31.69%
1Y+45.60%
Valuation vs Sector

P/E of 75.43 is above the sector median of 40.02 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 75.4.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
75.43
Industry PE
40.02
Forward P/E est.
100.57
PEG Ratio
-
Book Value
₹52.87
Price to Book
1.89
P/S
0.80
EV/EBITDA
51.33
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
4.58%
Profit 5Y
1.71%
Revenue (YoY)
-56.30%
Earnings (YoY)
-25.00%

Profitability & Returns

ROCE
6.84%
ROE
2.64%
ROA
1.33%
Profit Margin
0.87%
Op Margin
1.07%
Gross Margin
3.82%
EPS (Latest Qtr)
₹0.55
EPS (TTM)
₹1.27

Balance Sheet & Liquidity

Debt/Equity
0.40
Quick Ratio
1.53
Current Ratio
1.81
Debt
₹60.75 Cr
Total Assets
₹297.25 Cr
Current Assets
₹262.94 Cr
Working Capital
₹117.87 Cr

Ownership

Promoter Holding
43.18%
Chg in Prom Hold
-0.31%
FII / Inst Holding
1.77%
Chg in FII Hold
0.87%

Financial Snapshot

Enterprise Value
₹319.50 Cr
Total Revenue (TTM)
₹414.69 Cr
EBITDA
₹6.66 Cr
Free Cash Flow
₹-2.27 Cr
Operating Cash Flow
₹10.14 Cr
Shares Outstanding
₹3.34 Cr
Gross Margin
3.82%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 AAREYDRUGS Aarey Drugs & Pharmaceuticals Limited NSEPHARMA 95.79 75.43 ₹319.50 Cr 0.00% 6.84% 2.64% 4.58% 1.71%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,895.00 37.64 ₹4.55 L Cr 0.85% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,315.00 84.60 ₹2.47 L Cr 0.31% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,914.00 78.62 ₹1.87 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.23% 19.20% 20.48% 14.85% 33.34%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 688.00 237.24 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,156.90 23.10 ₹1.16 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 33.25 ₹1.12 L Cr 0.94% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 90.86 ₹99,417.45 Cr 0.12% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -108.10 Cr102.21 Cr84.16 Cr96.43 Cr189.47 Cr
Cost of Revenue -109.18 Cr97.84 Cr80.48 Cr96.80 Cr179.39 Cr
Gross Profit --1.08 Cr4.37 Cr3.68 Cr-36.99 L10.08 Cr
Operating Expenses -3.54 Cr3.16 Cr1.73 Cr1.97 Cr6.59 Cr
Operating Income --4.61 Cr1.22 Cr1.95 Cr-2.34 Cr3.49 Cr
EBITDA -3.33 Cr3.25 Cr3.44 Cr2.67 Cr3.91 Cr
Interest Expense -1.30 Cr1.04 Cr1.26 Cr91.91 L1.78 Cr
Pretax Income -1.62 Cr1.73 Cr1.48 Cr92.37 L1.28 Cr
Tax Provision -1.15 Cr35.69 L45.82 L35.42 L-27.73 L
Net Income -47.01 L1.37 Cr1.02 Cr56.95 L1.56 Cr
Diluted EPS -0.170.480.360.200.55

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -412.85 Cr395.10 Cr473.94 Cr472.27 Cr
Cost of Revenue -403.84 Cr381.90 Cr462.06 Cr454.51 Cr
Gross Profit -9.01 Cr13.20 Cr11.88 Cr17.76 Cr
Operating Expenses -7.00 Cr10.38 Cr10.93 Cr13.44 Cr
Operating Income -2.00 Cr2.82 Cr95.39 L4.32 Cr
EBITDA -10.19 Cr11.35 Cr12.71 Cr13.27 Cr
Interest Expense -2.61 Cr4.31 Cr4.66 Cr5.00 Cr
Pretax Income -6.01 Cr5.34 Cr6.10 Cr5.41 Cr
Tax Provision -2.24 Cr65.93 L2.08 Cr1.45 Cr
Net Income -3.77 Cr4.68 Cr4.02 Cr3.97 Cr
Diluted EPS -1.491.841.421.39

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -291.32 Cr303.29 Cr290.59 Cr297.25 Cr
Current Assets -270.61 Cr282.59 Cr265.62 Cr262.94 Cr
Cash & Equivalents -70.58 L1.59 Cr1.47 Cr1.40 Cr
Inventory -28.82 Cr34.68 Cr45.49 Cr41.54 Cr
Receivables -189.78 Cr184.48 Cr133.46 Cr129.65 Cr
Total Liabilities -173.92 Cr170.54 Cr152.11 Cr146.82 Cr
Current Liabilities -168.14 Cr166.55 Cr149.21 Cr145.08 Cr
Long Term Debt -4.36 Cr3.22 Cr1.99 Cr97.40 L
Total Debt -37.72 Cr31.35 Cr34.86 Cr49.96 Cr
Total Equity -117.41 Cr132.76 Cr138.48 Cr150.42 Cr
Shares Outstanding -2.54 Cr2.81 Cr2.85 Cr2.84 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow --1.28 Cr-2.99 Cr10.30 Cr10.14 Cr
Investing Cash Flow -44.10 L-1.70 Cr-5.94 Cr-12.41 Cr
Financing Cash Flow -1.35 Cr5.58 Cr-4.48 Cr2.20 Cr
Capital Expenditure --1.04 Cr-72.23 L-5.20 Cr-12.41 Cr
Free Cash Flow --2.33 Cr-3.72 Cr5.10 Cr-2.27 Cr
Net Change in Cash -51.39 L88.87 L-12.11 L-7.47 L

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -2.2%3.3%2.5%3.8%
Operating Margin % -0.5%0.7%0.2%0.9%
Net Margin % -0.9%1.2%0.8%0.8%
ROE % -3.2%3.5%2.9%2.6%
ROCE % -1.6%2.1%0.7%2.8%

Shareholding Pattern

Insiders
43.18%
Institutions
1.77%
Public Float
3.11%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AAREYDRUGS

Google News Fri, 04 Sep 2026

Aarey Drugs Share Price: Buy or Sell - Univest

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxNM0ZtQUNMTTlJNlBiTVJZblN5d195bVJPaXhPc2R4cHdJakNoUUVRZWNRUUdwckNVZnJmSmhZa3lTU3lBVFdiOEpFY0YydHBJbDdTbXlrckhQcFJHTEF1VmlFckNaQWNiTkhtekF0RV9aWHRnc205d09pVmxOMnlaeGJrWlBXTlFlQlJncV…

Google News Sun, 21 Jun 2026

Aarey Drugs & Pharmaceuticals Holds Steady Near ₹82 Amid Range-bound Trading - Fear Greed Index - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxOOTlaRnJrQ0pxQUVMLU9qUVBDNUczT01vaW9GdmJHdGR3VkJfekM5R0hXcUFTb2t5ZUN6eXpDbGJkbWNPSUR5MXRmT2JVX1VabC1WQ1dPSjVhZ1hhRzZkR3pVZG5Ed1NLYVoycFQwV1FRWWxIR2EzYnRZMXpUOHdCVFBteGIyMmRwbC1Tak…

Google News Sun, 21 Jun 2026

Aarey Drugs & Pharmaceuticals Holds Steady Near ₹82 Amid Range-bound Trading - Dip Buy Trade - siam.in

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxOVXMxYVVIY09RMUgwbU5CNS1XMklMY25PMGRJSU1BX2tWdHNDZkg3V2VGWFFmUjdpZzVfaElLZGZkWXpnOERSeTJaUzlZSjloTmE3dTV4ZmNSZjZIWXRrR1JzYnVsVldaZl9pajJfN1I0ZDFvRjg5X0I3SlR2Vy1HRjFRNW8tbzNSVnJLMm…

Google News Wed, 08 Jul 2026

Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Declines Nearly 2%; Faces Key Support Test at ₹81.93 - Hull Moving Average - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxOLTZ3RldZcVEyYU5HaVoxNTVoS2NaczllRUJWWXYwbWI4R1g2NjBVNFFlaTQybzhTUklsamVKR3pIT1BaTTRNc2tlWGF3MkpuOURhYnotdUZtZ2J0MUt0emhJREhoWEVRaUxJXzFoNEMwY0pfbk10VVBnenZnUlJDN1BPMmo1U1ZkMmZVbU…

Google News Sun, 30 Jul 2023

Aarey Drugs & Pharmaceuticals Ltd. - Stocktwits

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1lMnItbGhQWkRtQ1hLa0pweXRpSTBiTXcwdFNleFlwLWFsM1V6V0VLZmdLaE1FYkRlSjR4dUd0S1llRmJjSVhDOHp1NzJxR1liaDgyZkxFVjQyRDZNOTZB?oc=5" target="_blank">Aarey Drugs & Pharmaceuticals Ltd.</a>&…

Google News Fri, 06 Aug 2021

AAREYDRUGS Stock Price and Chart — NSE:AAREYDRUGS - TradingView

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE5NYm5rMjMxdHRZYzJLcnQ3b1gwSVdndzVfMVBwVEFoQjFDRkZwc1FuaFlyaGlwZnE1R2ZLODVJN0ZWNE1QNTJuSzctVDJJR0pZUWtrbVJhOVBCOTdRRHBqUA?oc=5" target="_blank">AAREYDRUGS Stock Price and Chart — NS…

AAREYDRUGS — Frequently Asked Questions

What is the current share price of Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)?

As of 2026-09-20 09:43 IST, Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) trades at ₹95.79 on NSE. Its 52-week range is ₹50.75 to ₹99.25.

What is the market capitalisation of AAREYDRUGS?

Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) has a market capitalisation of ₹319.50 Cr on NSE.

What is the P/E ratio of AAREYDRUGS?

AAREYDRUGS trades at a trailing price-to-earnings (P/E) ratio of 75.43. The industry average P/E is 40.02. Its price-to-book (P/B) ratio is 1.89.

What is the return on equity (ROE) of AAREYDRUGS?

AAREYDRUGS has a return on equity (ROE) of 2.64%. Its return on capital employed (ROCE) is 6.84%.

Is AAREYDRUGS a good stock to buy?

This page provides a data-driven analysis of Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space